MedDataX Logo

The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico

NCT ID: NCT02831699

Last Updated: 2020-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-21

Study Completion Date

2019-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate subjects with fever and/or rash to determine the percentage of those infected by the Zika, Chikungunya, or Dengue virus. The study will also compare the clinical signs, symptoms, and lab abnormalities related to each virus, to better specify each virus's characteristics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will enroll subjects in several different cohorts including a febrile rash cohort (attempting to capture acute Zika/Chikungunya/Dengue infection), a household cohort (attempting to capture asymptomatic or minimally symptomatic subjects), and a cohort of those with Guillain Barré). Additionally, two subpopulations of the febrile rash cohort that have special follow up. This includes the pregnant population, who will be followed through delivery to determine pregnancy outcomes, and those subjects with neurologic or cognitive manifestations who will be evaluated to determine the spectrum of neurologic disease seen with these diseases.

Subjects with Guillain Barré with potential exposure to Zika virus are of special interest given the severity of disease. Subjects with Guillian Barré do not need to have a preceding illness suggestive of Zika or other viruses. As there are few subjects with Guillain Barré, subjects will be enrolled in two ways - a prospective cohort for subjects with acute Guillain Barré, and a cohort for subjects that had Guillain Barré in the last several years. Data collected systematically from these cohorts will improve the understanding of Zika/Chikungunya/Dengue virus infections.

There are many uncertainties about the number of subjects that meet this case definition. There are limits to the ability to enroll based on staffing and other resources. If there are many cases, an emphasis will be placed on enrolling pregnant subjects and adults with neurologic complications that meet the case definition, as this is the area of highest clinical need. If there are few pregnant women or subjects with neurologic problems that can be enrolled, then any adults or children meeting the criteria can be enrolled. Not all cohorts will be active at all sites, based on the type of facility and type of patients typically seen. If sufficient numbers of certain populations are enrolled (i.e. children born to women infected with Zika), the protocol may be amended to study those populations in more detail.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Zika Virus Disease (Disorder) Dengue Chikungunya

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Zika Guillain Barré

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Febrile Rash

No interventions assigned to this group

Household

No interventions assigned to this group

Guillain-Barré prospective

No interventions assigned to this group

Prior Guillain-Barré

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects with fever and/or rash will be included if they are 1 year of age or older, and meet one of the following criteria (1 or 2):

1. Meeting the WHO/PAHO case definition, as defined as (a and b and c):

1. One or both of the following primary signs:

* Rash
* Elevated body temperature (\> 37.2 °C) AND
2. One or more of the following symptoms (not explained by other medical conditions):

* Arthralgia
* Myalgia
* Non-purulent conjunctivitis or conjunctival hyperemia
* Headache
* Malaise AND
3. Onset of illness in the last 7 days
2. Modified case definition (a and b):

1. Any two of the following:

* Rash
* Elevated body temperature (\> 37.2 °C)
* Arthralgia
* Myalgia
* Non-purulent conjunctivitis or conjunctival hyperemia
* Headache
* Malaise AND
2. Onset of illness in the last 7 days


1. 1 year of age and older, and
2. Either live in the same household as a subject enrolled into the febrile rash cohort OR live in the same household as a subject who is experiencing an illness similar to Zika (fever and rash as previously described), regardless if said subject is enrolled in the study.


Either confirmed or suspected Guillain-Barré (areflexic flaccid paralysis) as defined either of the following:

1. Confirmed Guillain-Barré

1. Acute onset of weakness or paralysis (from baseline to full weakness in 20 days)
2. Weakness is symmetrical
3. Areflexic (reflexes are 0/4)
2. Suspected Guillain-Barré

1. Acute onset of illness
2. Areflexic flaccid paralysis


1. Confirmed Guillain-Barré

1. Acute onset of weakness or paralysis (from baseline to full weakness in 7 days)
2. Weakness is symmetrical
3. Areflexic (reflexes are 0/4)
4. Diagnosis since January 2014
2. Suspected Guillain-Barré

1. Acute onset of illness
2. Areflexic flaccid paralysis
3. Clinical diagnosis of Guillain-Barré
4. Diagnosis since January 2014
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Secretaria de Salud, Mexico

OTHER_GOV

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Mexican Emerging Infectious Diseases Clinical Research Network

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sophia Siddiqui

Role: STUDY_CHAIR

National Institute of Allergy and Infectious Diseases (NIAID)

Guillermo Ruiz-Palacios

Role: STUDY_CHAIR

Mexican Emerging Infectious Diseases Clinical Research Network

Pablo Francisco Belaunzarán Zamudio

Role: PRINCIPAL_INVESTIGATOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital General de Tapachula

Tapachula, Chiapas, Mexico

Site Status

Hospital Regional de Alta Especialidad Ciudad Salud

Chiapas, , Mexico

Site Status

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Clínica Hospital Dr. Roberto Nettel Flores

Chiapas, , Mexico

Site Status

Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Hospital General de Zona con Medicina Familiar No. 1

Chiapas, , Mexico

Site Status

Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Unidad de Medicina Familiar No. 11

Chiapas, , Mexico

Site Status

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Mexico City, , Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

References

Explore related publications, articles, or registry entries linked to this study.

Belaunzaran-Zamudio PF, Rincon Leon HA, Caballero Sosa S, Ruiz E, Najera Cancino JG, de La Rosa PR, Guerrero Almeida ML, Powers JH 3rd, Beigel JH, Hunsberger S, Trujillo K, Ramos P, Arteaga-Cabello FJ, Lopez-Roblero A, Valdes-Salgado R, Arroyo-Figueroa H, Becerril E, Ruiz-Palacios G; Mexican Emerging Infectious Diseases Clinical Research Network (La Red). Different epidemiological profiles in patients with Zika and dengue infection in Tapachula, Chiapas in Mexico (2016-2018): an observational, prospective cohort study. BMC Infect Dis. 2021 Aug 28;21(1):881. doi: 10.1186/s12879-021-06520-x.

Reference Type DERIVED
PMID: 34454432 (View on PubMed)

Belaunzaran-Zamudio PF, Ortega-Villa AM, Mimenza-Alvarado AJ, Guerra-De-Blas PDC, Aguilar-Navarro SG, Sepulveda-Delgado J, Hunsberger S, Salgado RV, Ramos-Castaneda J, Rincon Leon HA, Rodriguez de La Rosa P, Najera Cancino JG, Beigel J, Caballero Sosa S, Ruiz Hernandez E, Powers JH 3rd, Ruiz-Palacios GM, Lane C. Comparison of the Impact of Zika and Dengue Virus Infection, and Other Acute Illnesses of Unidentified Origin on Cognitive Functions in a Prospective Cohort in Chiapas Mexico. Front Neurol. 2021 Mar 22;12:631801. doi: 10.3389/fneur.2021.631801. eCollection 2021.

Reference Type DERIVED
PMID: 33828518 (View on PubMed)

Gouel-Cheron A, Lumbard K, Hunsberger S, Arteaga-Cabello FJ, Beigel J, Belaunzaran-Zamudio PF, Caballero-Sosa S, Escobedo-Lopez K, Ibarra-Gonzalez V, Najera-Cancino JG, Rincon-Leon HA, Ruiz-Hernandez E, Sepulveda-Delgado J, Trujillo-Murillo K, Ruiz-Palacios G. Serial real-time RT-PCR and serology measurements substantially improve Zika and Dengue virus infection classification in a co-circulation area. Antiviral Res. 2019 Dec;172:104638. doi: 10.1016/j.antiviral.2019.104638. Epub 2019 Oct 28.

Reference Type DERIVED
PMID: 31672665 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Zik01

Identifier Type: -

Identifier Source: org_study_id